The timing of disease onset may hold crucial clues for extending healthy lifespan, but until now, researchers lacked effective tools to analyze how rare genetic variants influence when conditions develop. This computational breakthrough could accelerate the discovery of protective genes that delay aging-related diseases. The research introduces a novel statistical framework that can analyze rare genetic variants—mutations found in less than 1% of the population—specifically for their impact on disease timing across massive genomic databases. Unlike common variants studied in traditional genome-wide association studies, these rare mutations often have larger biological effects but require specialized analytical approaches to detect meaningful patterns. The new method addresses a critical gap in genetic epidemiology by handling time-to-event data, which tracks not just whether someone develops a condition, but when it occurs. This temporal dimension is essential for understanding diseases like cardiovascular events, cancer onset, or neurodegenerative conditions where timing significantly affects treatment outcomes and quality of life. From a longevity perspective, this methodology represents a significant advancement in precision aging research. By identifying rare variants that either accelerate or delay disease onset, researchers can better understand the genetic architecture of healthspan—the period of life free from major illness. The ability to process whole genome sequencing data from large biobanks means findings will have robust statistical power and population-level relevance. However, the clinical translation remains complex. Rare variants by definition affect small population segments, making therapeutic development challenging. Additionally, the method's computational requirements may limit accessibility for smaller research institutions, potentially concentrating genetic insights within well-resourced centers.